News & Updates

Show Multimedia Only

Evolving role of lenvatinib in management of unresectable HCC

20 Feb 2026 by

At an industry-sponsored symposium during the International Liver Cancer Association (ILCA) 2025 Annual Conference, Dr Krittiya Korphaisarn of Mahidol University, Bangkok, Thailand, reviewed systemic therapy for advanced hepatocellular carcinoma (HCC), focusing on lenvatinib as a second-line (2L) option following immunotherapy (IO). Professor Joseph Llovet of the University of Barcelona, Barcelona, Spain, and Tisch Cancer Institute at Mount Sinai, New York, US, and Professor Masatoshi Kudo of the Kindai University, Osaka, Japan, discussed the integration of systemic and locoregional treatments for intermediate HCC to optimize outcomes through multidisciplinary care.

Evolving role of lenvatinib in management of unresectable HCC

20 Feb 2026

Predictive model spots genes linked to more aggressive ATC

18 Feb 2026

A new genomic predictive model has identified mutated genes that are associated with the most aggressive anaplastic thyroid cancer (ATC), according to a study.

Predictive model spots genes linked to more aggressive ATC

18 Feb 2026

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026 by

Ultraprocessed foods (UPFs) are associated with several preventable diseases and must be viewed not only through a nutritional lens but also as addictive, industrially engineered substances, which can be likened to cigarettes, suggests a recent study.

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

13 Feb 2026 by

A 67-year-old man was diagnosed with polycythaemia vera (PV) in 2005. Over the next several years, he received various cytoreductive agents, including anagrelide, pegylated interferon (IFN) and hydroxyurea.

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

13 Feb 2026

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

13 Feb 2026

Updated results of the phase II PHAROS study of encorafenib plus binimetinib, a BRAF plus MEK inhibitor combination that has recently become available in Hong Kong, include a median overall survival (mOS) of 47.6 months in treatment-naïve patients and 22.7 months in previously treated patients with BRAF^V600E-mutant metastatic non-small-cell lung cancer (mNSCLC).

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

13 Feb 2026

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026 by

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

11 Feb 2026

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

10 Feb 2026 by

The patient was a female in her early 50s, who presented was constitutional symptoms, including weight loss and fatigue, in June 2022. Baseline FDG-PET scan discovered a 9 cm highly avid liver mass, with multiple intrahepatic and lymph node metastases. The patient was put on the TOPAZ-1 regimen (durvalumab 1,500 mg on day 1 plus gemcitabine 1,000 mg/m² and cisplatin 25 mg/m²on days 1 and 8 of a 21-day cycle for a total of 8 cycles followed by durvalumab monotherapy Q4W thereafter). A follow-up FDG-PET after 8 cycles showed quiescence across all lesions, indicating complete metabolic response. Last seen in August 2025, the patient was alive and well, with an ongoing PFS of 39 months.

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

10 Feb 2026

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

08 Feb 2026

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

08 Feb 2026

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026 by

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

GLP-1RA bests aspirin for CRC prevention

06 Feb 2026

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026 by

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

06 Feb 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Evolving role of lenvatinib in management of unresectable HCC

Evolving role of lenvatinib in management of unresectable HCC

Predictive model spots genes linked to more aggressive ATC

Predictive model spots genes linked to more aggressive ATC

Ultraprocessed foods are the new cigarettes: study

Ultraprocessed foods are the new cigarettes: study

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

JAK1/2 inhibitor provides rapid and durable disease control in a patient with myelofibrosis

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

mOS of nearly 4 years in Tx-naïve BRAFV600E-mutant mNSCLC with combination therapy newly available in HK

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Nivolumab-ipilimumab combo plus surgery improves survival in HCC

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

Ongoing PFS of >3 years in a patient with metastatic cholangiocarcinoma treated with durvalumab + chemotherapy

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

PFS gains seen with savolitinib–osimertinib combo in EGFR-mutant, MET-amplified NSCLC

GLP-1RA bests aspirin for CRC prevention

GLP-1RA bests aspirin for CRC prevention

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA

Zanidatamab outdoes trastuzumab as first-line treatment of HER2-positive mGEA